2. Search Result
Search Result
Results for "

Dexrazoxane

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0581
    Dexrazoxane
    Maximum Cited Publications
    12 Publications Verification

    ICRF-187; ADR-529; NSC-169780

    		 Ferroptosis Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .
    Dexrazoxane
  • HY-76201
    Dexrazoxane hydrochloride
    Maximum Cited Publications
    12 Publications Verification

    ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride

    		 Others Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a heart protectant that can help preserve ovarian function and fertility. Dexrazoxane hydrochloride has antioxidant and anti-inflammatory properties, can cross the blood-brain barrier, improves motor function disorders, and offers neuroprotective effects, making it useful in the study of neurodegenerative diseases .
    Dexrazoxane hydrochloride
  • HY-110075
    Dexrazoxane monohydrochloride

    		Others Cardiovascular Disease
    Dexrazoxane monohydrochloride is the hydrochloride of Dexrazoxane (HY-B0581). Dexrazoxane can prevent or reduce cardiac damage and is an iron chelator and apoptosis inducer. Dexrazoxane has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities and inhibits ferroptosis .
    Dexrazoxane monohydrochloride
  • HY-B0581R
    Dexrazoxane (Standard)

    		Ferroptosis Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Dexrazoxane (Standard) is the analytical standard of Dexrazoxane. This product is intended for research and analytical applications. Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .
    Dexrazoxane (Standard)
  • HY-124178
    (R)-Levrazoxane

    (R)-ICRF 186

    		 Drug Intermediate Metabolic Disease
    (R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases .
    (R)-Levrazoxane

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: